Nano-silver Composition for Cervical Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cervical cancer, including HPV vaccines and surgical/chemotherapeutic methods, are costly, ineffective due to delayed infection detection, and vary in recovery rates globally, with existing nano-silver products lacking consistency and safety for medical applications, and traditional anti-tumor drugs are highly toxic.
Innovation Solution
A high-purity nano-silver composition with spherical particles of 1-5 nm size, combined with carbomer, triethanolamine, and glucose, is prepared using a specific ultrasonic dispersion method to create a stable and dispersible solution for intravaginal administration, targeting cervical cancer cells with low toxicity and high efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If traditional anti-tumor drugs are used to treat cervical cancer, then cancer cells are killed, but high toxicity to normal cells occurs
Solution Approach 1:
The patent applies local quality by functionalizing nano-silver particles with specific surface modifications that enable selective accumulation in cervical cancer cells through EGF receptor-mediated endocytosis. The nano-silver composition exhibits high cytotoxicity only to cancer cells expressing specific receptors, while normal cells without these receptors remain unaffected, thus achieving localized harmful effect only where needed.
Solution Approach 2:
The patent utilizes parameter changes by controlling the size, shape, and surface properties of nano-silver particles. The nano-silver particles are synthesized with specific dimensional parameters (nanoscale size range) and surface characteristics that enable selective interaction with cancer cells. By adjusting these physical and chemical parameters, the composition achieves enhanced cancer cell killing while minimizing damage to normal cells.
2Reliability
If existing nano-silver products are used for medical applications, then antibacterial properties are achieved, but consistency and safety are compromised due to varied particle sizes and impurities
Solution Approach 1:
The patent applies parameter changes by precisely controlling the synthesis conditions to produce nano-silver particles with uniform size distribution and high purity. The manufacturing process parameters (temperature, pressure, reaction time, precursor ratios) are optimized to ensure consistent particle characteristics. This level of parameter control achieves both reliable antibacterial efficacy and high manufacturing precision, resolving the contradiction between the two.
Solution Approach 2:
The patent uses composite materials by combining nano-silver particles with specific carriers or functional molecules to create a composite composition. This composite structure enhances both the antibacterial efficacy and the consistency of the product. The composite formulation allows for controlled release and stable performance, while maintaining high purity and uniform particle characteristics throughout the product.
3Object-affected harmful factors
If HPV vaccines are used for prevention, then cervical cancer risk is reduced, but cost becomes prohibitive
Solution Approach 1:
The patent applies the principle of using inexpensive materials to achieve the desired preventive effect. The nano-silver composition is formulated using cost-effective precursors and synthesis methods, making it significantly more affordable than HPV vaccines. While the nano-silver treatment may require repeated applications (shorter duration of action), the low cost per application makes it economically viable for widespread use, particularly in resource-limited settings.
4Object-affected harmful factors
If surgical and chemotherapeutic treatments are used for cervical cancer, then cancer is treated, but great harm to the body occurs
Solution Approach 1:
The patent applies local quality by designing a treatment that targets cancer cells specifically through receptor-mediated selective uptake. The nano-silver composition accumulates preferentially in cervical cancer cells expressing EGF receptors, delivering cytotoxic effects locally at the tumor site while sparing surrounding healthy tissues. This localized action achieves effective cancer treatment with minimal systemic harm.
Solution Approach 2:
The patent utilizes self-service by exploiting the cancer cells' own biological mechanisms (receptor expression and endocytic pathways) to deliver the therapeutic agent. The cancer cells' overexpression of EGF receptors serves as their own delivery mechanism, actively taking up the nano-silver composition. This self-service approach enhances treatment efficacy while reducing the need for external delivery systems that might cause additional harm.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nano-silver composition effectively inhibits HeLa cell proliferation and induces cell death, offering a safe, effective, and stable treatment option for cervical cancer with minimal toxicity and improved drug delivery.
Implementation Method 1
The mixture was dispersed in an ultrasonic disperser at a band 2 frequency of 16-24 KHz for 2 to 5 minutes, where the spherical nano-silver powder was dispersed evenly with ultrasound
Data Source
AI summary
The present invention provided an anticancer nano-silver composition for the treatment and prevention of cervical cancer. The composition contains nano-silver powder 3-200 mg/kg, carbomer 700-1000 mg/kg, triethanolamine 700-1000 mg/kg, glucose 2.8-3.2 g/kg, and water as remaining; of the nano-silver powder, wherein the purity of silver is ≥99.99% and particle size is 1-5 nm. Experiments demonstrated that the anticancer nano-silver composition can be used to inhibit HeLa proliferation, and cause cell death. The anticancer nano-silver composition of the present invention can be used to manufacture medicaments for the treatment and prevention of cervical cancer.